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Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at similar potencies. The efficacy, safety and tolerability of adjunctive brexpiprazole were evaluated in patients with major depressive disorder (MDD) and inadequate response to antidepressant treatments (ADTs), based on pooled data from two pivotal phase III studies (NCT01360645 [1] ; NCT01360632 [2] ). Methods: Patients with MDD and inadequate response to 1-3 ADTs were enrolled and received single-blind ADT for 8 weeks. Patients with inadequate response after this prospective phase were randomized to ADT+brexpiprazole or ADT+placebo for 6 weeks. Both studies included fixed doses (2mg [Study 1: NCT01360645]; 1mg and 3mg [Study 2: NCT01360632]). Primary efficacy endpoint was the change in MADRS total score from baseline to Week 6. As the two studies had a similar design, a meta-analysis was performed with pooled placebo groups. Results: Adjunctive brexpiprazole showed greater improvement than adjunctive placebo in MADRS total score (least square mean difference to placebo+ADT [n=381]: 1mg+ADT [n=211]: -2.02, p=0.0018; 2mg+ADT [n=175]: -2.35, p=0.0007; 3mg+ADT [n=213]: -2.54, p=0.0001). The most frequent adverse events included akathisia (4.4%, 7.4%, 13.5%, 1.7%), weight increase (6.6%, 8.0%, 5.7%, 1.9%), tremor (4.0%, 2.1%, 5.2%, 2.2%) and somnolence (4.0%, 4.3%, 5.7%, 0.5%), in the brexpiprazole 1mg+ADT (n=226), 2mg+ADT (n=188), 3mg+ADT (n=229) and pooled placebo+ADT groups (n=411), respectively. Conclusion: Data from adequate and well-controlled clinical studies provide evidence that brexpiprazole is efficacious as adjunctive treatment in MDD patients with an inadequate response to ADTs. All doses of adjunctive brexpiprazole were well tolerated, with notably low levels of sedating or activating side effects.
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